Zentalis Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Zentalis Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Zentalis Pharmaceuticals Inc Strategy Report
- Understand Zentalis Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Zentalis Pharmaceuticals Inc (Zentalis Pharmaceuticals) formerly Zentalis Pharmaceuticals LLC, is a biopharmaceutical company that discovers and develops small molecule drugs to treat cancers. It is investigating its lead product candidate ZN-c3, a WEE1 inhibitor against uterine serous carcinoma, solid tumors, osteosarcoma, and ovarian cancer. The company is also evaluating ZN-c5, an oral SERD (selective estrogen receptor degrader) for the treatment of breast cancer; ZN-d5, a BCL-2 (B-cell lymphoma 2) inhibitor targeting hematologic malignancies; and ZN-e4, an EGFR (epidermal growth factor receptor) inhibitor to treat non-small cell lung carcinoma. Zentalis Pharmaceuticals utilizes its integrated discovery engine to identify and develop oncology therapies. The company works in collaboration with Pfizer Inc, Mayo Clinic and SciClone Pharmaceuticals Inc, among others. Zentalis Pharmaceuticals is headquartered in New York, the US.
Headquarters
United States of America
Address
1359 Broadway, Suite 801, New York, 10018
Website
www.zentalis.com
Telephone
1 212 4333791
No of Employees
168
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZNTL (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-23.4%
(2022 vs 2021)
Market Cap*
$779.5M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Zentalis Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| ZN-c3: |
| Uterine Serous Carcinoma |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Zentalis Pharmaceuticals Inc | Merck & Co Inc | Vanda Pharmaceuticals Inc | Alaunos Therapeutics Inc | 21st Century Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York | Kenilworth | Washington | Houston | Detroit |
| State/Province | New York | New Jersey | WashingtonD.C. | Texas | Michigan |
| No. of Employees | 168 | 72,000 | 203 | 1 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dave Johnson | Chairman | Executive Board | 2022 | 58 |
| Kimberly Blackwell | Chief Executive Officer; Director | Executive Board | 2022 | 54 |
| Diana Hausman, M.D. | Director; Chief Medical Officer | Executive Board | 2024 | - |
| Cam S Gallagher | President; Director | Executive Board | 2022 | 53 |
| Kimberly Freeman | Chief Strategy Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer